ES2085133T3 - Compuestos de imidazol, su preparacion y su uso. - Google Patents

Compuestos de imidazol, su preparacion y su uso.

Info

Publication number
ES2085133T3
ES2085133T3 ES93610022T ES93610022T ES2085133T3 ES 2085133 T3 ES2085133 T3 ES 2085133T3 ES 93610022 T ES93610022 T ES 93610022T ES 93610022 T ES93610022 T ES 93610022T ES 2085133 T3 ES2085133 T3 ES 2085133T3
Authority
ES
Spain
Prior art keywords
alkyl
amino
alkoxy
nitro
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93610022T
Other languages
English (en)
Inventor
Oskar Axelsson
Dan Peters
Elsebet Ostergaard Nielsen
Palle Christophersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Application granted granted Critical
Publication of ES2085133T3 publication Critical patent/ES2085133T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polymerization Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCION PONE A DISPOSICION COMPUESTOS DE LA FORMULA DONDE X ES C O N; Y ES C O N; R11 ES HIDROGENO, HIDROXI O ALCOXI; R12 Y R13 SON CADA UNO DE FORMA INDEPENDIENTE HIDROGENO; HALOGENO; CF3; CN; OH; ALQUIL; CICLOALQUIL; CICLOALQUILALQUIL; ALQUENIL; ALQUINIL; ALCOXI; FENILALCOXI; AMINO; NITRO; SULFAMOIL; PIPIRIDIL; PIRROLIDINIL; ACIL; CO2H; CO2 CO -O; NH CO CON HALOGENO, CF3, CN, OH, ALQUIL, ALQUENIL, ALQUINIL, ALCOXI, AMINO O NITRO; FENILOXI QUE PUEDE SER SUSTITUIDO CON HALOGENO, CF3, CH, OH, ALQUIL, ALQUENIL, ALQUINIL, ALCOXI, AMINO, O NITRO; FENILAMINO QUE PUEDE SER SUSTITUIDO CON HALOGENO, CF3, CN, OH, ALQUIL, ALQUENIL, ALQUINIL, ALCOXI, AMINO, O NITRO; O ARIL QUE PUEDE SER SUSTITUIDO UNA O MAS VECES CON HALOGENO, CF3, CN, OH, ALQUIL, CICLOALQUIL, CICLOALQUILALQUIL, ALQUENIL, ALQUINIL, ALCOXI, FENOXI, FENILALQUIL, AMINO, NITRO SULFAMOIL, PIPIRIDIL, PIRROLIDINIL, CO2H, CO2 ALQUIL; Y R4, R5, R6 Y R7 SON CADA UNO DE ELLOS DE FORMAN INDEPENDIENTE HIDROGENO; HALOGENO; AMINO; NITRO; CN; CF3, COOH; COO ES R4 ESTA AUSENTE Y SI Y ES N ENTONCES R7 ESTA AUSENTE; O UNA SAL DE ADICION ACEPTABLE FARMACEUTICAMENTE DE ELLOS LOS COMPUESTOS SON UTILIZABLES COMO PRODUCTOS FARMACEUTICOS, POR EJEMPLO EN EL TRATAMIENTO DE LA APOPLEJIA, ISQUEMIA, ANOXEMIA, MIGRAÑA Y PSICOSIS.
ES93610022T 1992-03-26 1993-03-24 Compuestos de imidazol, su preparacion y su uso. Expired - Lifetime ES2085133T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK92401A DK40192D0 (da) 1992-03-26 1992-03-26 Imidazolforbindelser, deres fremstilling og anvendelse

Publications (1)

Publication Number Publication Date
ES2085133T3 true ES2085133T3 (es) 1996-05-16

Family

ID=8093115

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93610022T Expired - Lifetime ES2085133T3 (es) 1992-03-26 1993-03-24 Compuestos de imidazol, su preparacion y su uso.

Country Status (15)

Country Link
US (1) US5360809A (es)
EP (1) EP0563001B1 (es)
JP (1) JP3647051B2 (es)
KR (1) KR100286844B1 (es)
AT (1) ATE134621T1 (es)
AU (1) AU660219B2 (es)
CA (1) CA2092211C (es)
DE (1) DE69301618T2 (es)
DK (2) DK40192D0 (es)
ES (1) ES2085133T3 (es)
FI (1) FI931305A (es)
GR (1) GR3019204T3 (es)
NO (1) NO303779B1 (es)
NZ (1) NZ247233A (es)
ZA (1) ZA932090B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU675484B2 (en) * 1993-03-24 1997-02-06 Neurosearch A/S Benzimidazole compounds, their use and preparation
US5554630A (en) * 1993-03-24 1996-09-10 Neurosearch A/S Benzimidazole compounds
RU2153494C2 (ru) * 1993-10-12 2000-07-27 Дзе Дюпон Мерк Фармасьютикал Компани 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция
PL313973A1 (en) * 1993-10-12 1996-08-05 Du Pont Merck Pharma 1 n-alkyl-n-arylopyrimidin amines and their derivatives
US5552426A (en) * 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide
WO1996033191A1 (en) * 1995-04-21 1996-10-24 Neurosearch A/S Benzimidazole compounds and their use as modulators of the gabaa receptor complex
US6228871B1 (en) 1995-07-10 2001-05-08 Merck & Co., Inc. Angiogenesis inhibitors
PT891332E (pt) * 1996-03-29 2004-07-30 Pfizer Derivados de 6-fenilpiridil-2-amina
JP2001502675A (ja) * 1996-10-21 2001-02-27 ニューロサーチ・アクティーゼルスカブ １―フエニル―ベンズイミダゾール化合物及びこれをｂａｇａ▲下ａ▼―レセプターモデュレーターとして使用する方法
GB9702524D0 (en) * 1997-02-07 1997-03-26 Merck Sharp & Dohme Therapeutic agents
US5990146A (en) * 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
EP1017682A4 (en) * 1997-09-26 2000-11-08 Merck & Co Inc NEW ANGIOGENESIS INHIBITORS
US6541479B1 (en) * 1997-12-02 2003-04-01 Massachusetts College Of Pharmacy Calcium channel blockers
JP2002523459A (ja) * 1998-08-31 2002-07-30 メルク エンド カムパニー インコーポレーテッド 新規血管形成阻害剤
EP1144387A1 (en) * 1998-12-04 2001-10-17 Neurosearch A/S New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
WO2000078728A1 (en) * 1999-06-22 2000-12-28 Neurosearch A/S Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds
GB9921150D0 (en) * 1999-09-07 1999-11-10 Merck Sharp & Dohme Therapeutic agents
AU783521B2 (en) 2000-05-24 2005-11-03 Merck Sharp & Dohme Limited 3-phenyl-imidazo-pyrimidine derivatives as ligands for GABA receptors
US7022480B1 (en) 2001-10-11 2006-04-04 The Regents Of The University Of California Exons of the hSKCa3/KCNN3 gene
GB0208392D0 (en) * 2002-04-11 2002-05-22 Merck Sharp & Dohme Therapeutic compounds
GB0208394D0 (en) * 2002-04-11 2002-05-22 Merck Sharp & Dohme Therapeutic agents
GB0212048D0 (en) 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
KR100998838B1 (ko) * 2003-03-13 2010-12-06 이데미쓰 고산 가부시키가이샤 신규한 질소 함유 헤테로환 유도체 및 이를 이용한 유기전기발광 소자
EP1613618A2 (en) * 2003-04-03 2006-01-11 Neurosearch A/S BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA- sb A /sb RECEPTOR COMPLEX
AP2006003549A0 (en) * 2003-08-21 2006-04-30 Osi Pharm Inc N-substituted benzimidazolyl C-kit inhibitors.
US7442709B2 (en) * 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
AU2004285053B2 (en) * 2003-10-28 2010-10-21 Vertex Pharmaceuticals, Incorporated Benzimidazoles useful as modulators of ion channels
EP1877052B1 (en) * 2005-04-13 2009-07-22 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
WO2006124865A2 (en) * 2005-05-19 2006-11-23 Vertex Pharmaceuticals Incorporated Biaryls derivatives useful as modulators of ion channels
US20090140637A1 (en) * 2005-07-11 2009-06-04 Idemitsu Kosan Co., Ltd. Nitrogen-containing heterocyclic derivative having electron-attracting substituent and organic electroluminescence element using the same
EP1956013B1 (en) * 2005-11-30 2016-04-13 Fujifilm RI Pharma Co., Ltd. Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
DE602006010602D1 (de) * 2005-12-05 2009-12-31 Neurosearch As Benzimidazolderivate und ihre verwendung zur modulierung des gabaa-rezeptorkomplexes
TWI391381B (zh) * 2006-03-24 2013-04-01 Neurosearch As 新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途
MX2010000918A (es) * 2007-07-24 2010-03-15 Astellas Pharma Inc Derivado de bencimidazol.
JP5507543B2 (ja) * 2008-04-29 2014-05-28 ノバルティス アーゲー アクチビン様受容体キナーゼ（ａｌｋ４またはａｌｋ５）阻害剤としてのイミダゾ−ピリジン誘導体
WO2010055133A1 (en) * 2008-11-14 2010-05-20 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
TW201029986A (en) * 2008-11-14 2010-08-16 Neurosearch As Novel compounds
TW201029987A (en) * 2008-11-14 2010-08-16 Neurosearch As Novel compounds
WO2010055130A1 (en) * 2008-11-14 2010-05-20 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
US20110282066A1 (en) 2009-01-27 2011-11-17 Takashi Furutani Screening method for substance useful as agent for treating prostate cancer
US8278460B2 (en) * 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
WO2012131501A1 (en) * 2011-03-28 2012-10-04 Glenmark Pharmaceuticals S.A. Substituted benzimidazole compounds as cot kinase inhibitors
CA3151555A1 (en) * 2013-04-04 2014-10-09 University Of Maryland, Baltimore Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
RS64792B1 (sr) * 2019-04-12 2023-11-30 Riboscience Llc Derivati bicikličnih heteroarila kao inhibitori ektonukleotid pirofosfataze fosfodiesteraze 1
CN112142622A (zh) * 2020-11-02 2020-12-29 江苏宝众宝达药业有限公司 一种4-氟-3-硝基苯腈的合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1570893A (es) * 1968-06-18 1969-06-13
HU190412B (en) * 1981-09-17 1986-09-29 Warner-Lambert Co,Us Process for producing substituted 4,5-dihiydro-6-bracket-substituted-bracket closed-phenyl-3-bracket-2h-bracket closed-pyridazinones and 6-bracket-substituted-bracket closed-phenyl-3-bracket-2h-bracket closed-pyridazinones
US4492708A (en) * 1982-09-27 1985-01-08 Eli Lilly And Company Antiviral benzimidazoles
US4734415A (en) * 1982-08-13 1988-03-29 Warner-Lambert Company Substituted 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinones and 6-(substituted) phenyl-3(2H)-pyridazinones
US4503061A (en) * 1983-07-22 1985-03-05 Warner-Lambert Company Substituted phenyl-pyridinones as cardiotonic agents
JPS59185691A (ja) * 1983-04-06 1984-10-22 Ricoh Co Ltd ジアゾ系感熱記録材料
US4550119A (en) * 1983-05-23 1985-10-29 Warner-Lambert Company 2,4-Dihydro-5-[(substituted)phenyl]-4,4-disubstituted-3H-pyrazol-3-ones
JPS61151176A (ja) * 1984-12-24 1986-07-09 Sumitomo Chem Co Ltd ベンズイミダゾール誘導体およびそれを有効成分とする殺虫、殺ダニ剤
MY104933A (en) * 1987-09-30 1994-07-30 Pfizer Ltd Platelet activating factor antagonists
FR2643903A1 (fr) * 1989-03-03 1990-09-07 Union Pharma Scient Appl Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
WO1991016313A1 (en) * 1990-04-13 1991-10-31 Smithkline Beecham Corporation Substituted benzimidazoles
GB9010637D0 (en) * 1990-05-11 1990-07-04 Secr Defence A high frequency multichannel diversity differential phase shift(dpsk)communications system
DE4015535A1 (de) * 1990-05-15 1991-11-21 Basf Ag Verfahren zur herstellung von n-substituierten imidazolen
PH31175A (en) * 1990-10-31 1998-03-20 Squibb & Sons Inc Indole and benzimi-dazole-substituted imidazole and benzimidazole derivatives.
EP0520200B1 (en) * 1991-06-24 1998-02-18 Neurosearch A/S Imidazole compounds, their preparation and use
US5210091A (en) * 1991-06-24 1993-05-11 Neurosearch A/S Imidazole compounds and their use

Also Published As

Publication number Publication date
DK40192D0 (da) 1992-03-26
JPH0649037A (ja) 1994-02-22
AU3540693A (en) 1993-09-30
KR930019638A (ko) 1993-10-18
FI931305A0 (fi) 1993-03-24
ATE134621T1 (de) 1996-03-15
DE69301618T2 (de) 1996-08-22
DE69301618D1 (de) 1996-04-04
DK0563001T3 (da) 1996-08-05
EP0563001A1 (en) 1993-09-29
JP3647051B2 (ja) 2005-05-11
EP0563001B1 (en) 1996-02-28
NO931080L (no) 1993-09-27
CA2092211A1 (en) 1993-09-27
CA2092211C (en) 2003-08-26
ZA932090B (en) 1993-10-15
NO303779B1 (no) 1998-08-31
GR3019204T3 (en) 1996-06-30
AU660219B2 (en) 1995-06-15
NZ247233A (en) 1995-03-28
NO931080D0 (no) 1993-03-24
US5360809A (en) 1994-11-01
FI931305A (fi) 1993-09-27
KR100286844B1 (ko) 2001-04-16

Similar Documents

Publication Publication Date Title
ES2085133T3 (es) Compuestos de imidazol, su preparacion y su uso.
FI935801A (fi) Imidatsoliyhdisteitä, niiden valmistus ja käyttö
BR9304815A (pt) Composição fungicida, e, processos para controlar fungos fitopatogênicos, e, para preparar compostos N-acetonil benzamida
BR9400808A (pt) Composto, processo para sua preparação, composição fungicida, método de combater fungos e uso
DE69331843D1 (de) Xanthine-Derivate als Antidepressiva
FI944417A0 (fi) Atsoliyhdisteet, niiden valmistus ja käyttö
ZA929268B (en) Imidazole compounds, their preparation and use.
HU906265D0 (en) Fungicide preparations containing aniline derivatives as active agents and process for the production of the active agents
BR8301067A (pt) Processo para a preparacao de eteres azoliletil-oximinoalquilicos substituidos,composicoes fungicidas,processos para o combate de fungos e para a preparacao de composicoes

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 563001

Country of ref document: ES